[Current Status of Drug Development for Amyotrophic Lateral Sclerosis]

Area of Science:

• Neurology
• Neuroscience
• Motor Neuron Diseases

Background:

• Amyotrophic lateral sclerosis (ALS) is a progressive, fatal neurodegenerative disorder affecting motor neurons.
• Current treatments like riluzole and edaravone offer limited efficacy, highlighting the critical need for novel therapeutic strategies.
• Rapid motor impairment characterizes ALS, emphasizing the urgency for effective interventions.

Purpose of the Study:

• To summarize the current landscape of amyotrophic lateral sclerosis (ALS) research and clinical trials.
• To underscore the unmet need for more effective ALS treatments.
• To highlight recent advancements facilitating clinical trial development.

Main Methods:

• Review of current therapeutic approvals for ALS.
• Analysis of progress in understanding ALS pathomechanisms.
• Examination of clinical trial design and research support initiatives.

Main Results:

• Despite existing treatments, ALS remains a lethal disease with significant unmet needs.
• Advances in understanding disease mechanisms and trial design are accelerating research.
• Numerous domestic and international clinical trials are underway for ALS.

Conclusions:

• There is a critical and ongoing need for more effective treatments for amyotrophic lateral sclerosis.
• Progress in basic science and clinical research methodologies is fostering new therapeutic development.
• The increasing number of clinical trials reflects a concerted global effort to combat ALS.